Objectives

After participating in this educational activity, attendees should be able to:
1. Discuss and understand the renal and cardiovascular indications and effectiveness for these agents to reduce renal and cardiovascular risk
2. Discuss and understand how these agents impact serum creatinine and volume status
3. Overcome clinical inertia and fear of adverse effects of these agents
4. Learn how to implement the use of SGLT2 inhibitors in patients on other medications for the treatment of CKD, DM II, and heart failure
 

Faculty

Speaker Name
Barbara Greco, MD
Nephrology Director, Baystate Transplant Program
Associate Program Director, Baystate Renal Fellowship
Renal and Transplant Associates of New England

Cecilia Davis, MD
Assistant Professor, Department of Medicine, UMMS-Baystate

Leeor Jaffe, MD
Advanced Heart Disease Cardiologist
Department of Cardiology, Baystate Medical Center

Chelsea Gordner, MD, MPH
Assistant Professor, Adult and Pediatric Endocrinology, Baystate Medical Center

Faculty Disclosure

The design and content of Baystate Continuing Interprofessional Education ( CE ) activities support quality improvement in healthcare and provide fair and balanced views of therapeutic options.  Faculty or planner conflicts of interest are resolved before the educational activity.

None of the planners or faculty for this educational activity have relevant financial relationship(s) to disclose with ineligible companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.  .